Patento informacija

EN | LT

LT - Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

EN - Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

Teisinis statusas

Patentas neįsigaliojo (pagal EPK)

Bibliografiniai duomenys

Tarptautinės patentų klasifikacijos indeksai (TPK)
(51)	INT.CL.	A61K 45/06
		A61P 35/00
		A61K 31/5377

Europos patentas
(11)	Patento numeris	2259800
(13)	Dokumento rūšis	T
(96)	Europos patento paraiškos numeris	09716778.7
	Europos patento paraiškos padavimo data	2009-03-04
(97)	Europos patento paraiškos paskelbimo data	2010-12-15
(45)	Paskelbimo apie Europos patento išdavimą data	2014-05-07
(46)	Apibrėžties vertimo paskelbimo data

Tarptautinės paraiškos padavimo
(86)	Numeris	PCT/EP2009/052564
	Data	2009-03-04

Tarptautinės paraiškos paskelbimo
(87)	Numeris	WO 2009/109605
	Data	2009-09-11

Prioriteto paraiškos
(30)	Numeris	Data	Šalis
	08152326	2008-03-05	EP

Išradėjai
(72)	GARCIA-ECHEVERRIA, Carlos, CH MAIRA, Sauveur-Michel, FR

Savininkas
(73)	Novartis AG, Lichtstrasse 35, 4056 Basel, CH

Pavadinimas
(54)	Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.
	Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.